Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment Highlighting Key Learnings from First-In-Human Trial and Extension into Visceral Cancer Pain
Autonomix Medical (NASDAQ: AMIX) has participated in a Virtual Investor "What This Means" segment featuring Chief Medical Officer Dr. Robert Schwartz. The discussion focused on two key aspects: the successful completion of their initial first-in-human proof-of-concept trial (PoC 1), which demonstrated meaningful pain reduction, and their plans for a market expansion study (PoC 2). The PoC 2 trial, scheduled to begin in Q2 2025, will evaluate their technology's effectiveness in treating pain across additional visceral cancers and earlier-stage pancreatic cancer. The company's technology focuses on using transvascular energy to ablate problematic nerves for pain mitigation in cancer patients.
Autonomix Medical (NASDAQ: AMIX) ha partecipato a una sessione virtuale per investitori intitolata "Cosa significa questo", con la partecipazione del Chief Medical Officer, il dottor Robert Schwartz. La discussione si è concentrata su due aspetti principali: il completamento con successo del loro primo studio proof-of-concept sull'uomo (PoC 1), che ha dimostrato una significativa riduzione del dolore, e i piani per uno studio di espansione del mercato (PoC 2). Il trial PoC 2, previsto per il secondo trimestre del 2025, valuterà l'efficacia della loro tecnologia nel trattamento del dolore in ulteriori tipi di tumori viscerali e nel cancro pancreatico in fase iniziale. La tecnologia dell'azienda si basa sull'uso di energia transvascolare per ablare i nervi problematici al fine di alleviare il dolore nei pazienti oncologici.
Autonomix Medical (NASDAQ: AMIX) ha participado en un segmento virtual para inversores titulado "Qué significa esto", con el director médico, el Dr. Robert Schwartz. La discusión se centró en dos aspectos clave: la exitosa finalización de su primer ensayo de prueba de concepto en humanos (PoC 1), que demostró una reducción significativa del dolor, y sus planes para un estudio de expansión de mercado (PoC 2). El ensayo PoC 2, programado para comenzar en el segundo trimestre de 2025, evaluará la efectividad de su tecnología en el tratamiento del dolor en otros cánceres viscerales y en el cáncer de páncreas en etapas tempranas. La tecnología de la compañía se enfoca en usar energía transvascular para ablacionar nervios problemáticos y así mitigar el dolor en pacientes con cáncer.
Autonomix Medical (NASDAQ: AMIX)는 최고 의료 책임자인 로버트 슈워츠 박사와 함께 "이것이 의미하는 바"라는 가상 투자자 세션에 참여했습니다. 논의는 두 가지 주요 측면에 집중되었습니다: 인간 대상 최초 개념 증명 시험(PoC 1)의 성공적인 완료로 의미 있는 통증 감소를 입증했으며, 시장 확장 연구(PoC 2)에 대한 계획입니다. PoC 2 시험은 2025년 2분기에 시작될 예정이며, 추가 내장암과 초기 단계 췌장암에서 통증 완화에 대한 기술의 효과를 평가할 것입니다. 회사의 기술은 암 환자의 통증 완화를 위해 문제성 신경을 혈관 내 에너지로 소작하는 데 중점을 두고 있습니다.
Autonomix Medical (NASDAQ : AMIX) a participé à une session virtuelle pour investisseurs intitulée « Ce que cela signifie », avec le directeur médical, le Dr Robert Schwartz. La discussion a porté sur deux points clés : la réussite de leur premier essai proof-of-concept chez l'humain (PoC 1), qui a démontré une réduction significative de la douleur, et leurs plans pour une étude d'expansion du marché (PoC 2). L'essai PoC 2, prévu pour le deuxième trimestre 2025, évaluera l'efficacité de leur technologie dans le traitement de la douleur liée à d'autres cancers viscéraux et au cancer du pancréas à un stade précoce. La technologie de l'entreprise repose sur l'utilisation d'énergie transvasculaire pour ablater les nerfs problématiques afin d'atténuer la douleur chez les patients atteints de cancer.
Autonomix Medical (NASDAQ: AMIX) nahm an einem virtuellen Investoren-Segment "Was das bedeutet" mit Chief Medical Officer Dr. Robert Schwartz teil. Die Diskussion konzentrierte sich auf zwei wichtige Aspekte: den erfolgreichen Abschluss ihrer ersten Proof-of-Concept-Studie am Menschen (PoC 1), die eine bedeutende Schmerzlinderung zeigte, und ihre Pläne für eine Markterweiterungsstudie (PoC 2). Die PoC 2-Studie, die im zweiten Quartal 2025 beginnen soll, wird die Wirksamkeit ihrer Technologie bei der Behandlung von Schmerzen bei weiteren viszeralen Krebserkrankungen und frühem Bauchspeicheldrüsenkrebs untersuchen. Die Technologie des Unternehmens nutzt transvasculare Energie, um problematische Nerven zur Schmerzlinderung bei Krebspatienten zu veröden.
- None.
- None.
Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses key learnings from initial trial phase (“POC 1”) where clinically meaningful pain reduction was demonstrated
Outlines Company’s plans to initiate market expansion study (“POC 2”) into additional visceral cancers and earlier stage pancreatic cancer, expected to begin Q2 2025
Access the “What This Means” video here
THE WOODLANDS, TX, May 01, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it recently participated in a Virtual Investor “What This Means” segment.
For the segment, Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discussed the Company’s successfully met initial phase of the first-in-human proof-of-concept trial (“PoC 1”) and the advancement to a follow-on phase (“PoC 2”) evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain.
The “What This Means” video can be accessed here.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
FAQ
What were the key results from Autonomix Medical's (AMIX) first-in-human trial?
When will Autonomix Medical (AMIX) begin its PoC 2 market expansion study?
What is the main technology being developed by Autonomix Medical (AMIX)?
What conditions will be studied in Autonomix Medical's (AMIX) PoC 2 trial?
